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Abstract 
Every day thousands of surgical procedures are performed to replace or repair tissue that has 
been damaged through disease or trauma. The developing field of tissue engineering (TE) 
aims to regenerate damaged tissues by combining cells from the body with highly porous 
scaffold biomaterials, which act as templates for tissue regeneration, to guide the growth of 
new tissue. This article describes the functional requirements, and types, of materials used in 
developing state of the art of scaffolds for tissue engineering applications. Furthermore, it 
describes the challenges and where future research and direction is required in this rapidly 
advancing field.    
 
Overview 
Disease, injury and trauma can lead to damage and degeneration of tissues in the human 
body, which necessitates treatments to facilitate their repair, replacement or regeneration.  
Treatment typically focuses on transplanting tissue from one site to another in the same 
patient (an autograft) or from one individual to another (a transplant or allograft). While these 
treatments have been revolutionary and lifesaving, major problems exist with both 
techniques. Harvesting autografts is expensive, painful, constrained by anatomical limitations 
and associated with donor-site morbidity due to infection and hematoma. Similarly, allografts 
and transplants also have serious constraints due to problems with accessing enough tissue 
for all of the patients who require them and the fact that there are risks of rejection by the 
patient’s immune system and the possibility of introducing infection or disease from the 
donor to the patient. Alternatively, the field of tissue engineering (a phrase that is 
interchangeably used with regenerative medicine) aims to regenerate damaged tissues, 
instead of replacing them, by developing biological substitutes that restore, maintain or 
improve tissue function1-3.  
 
The term ‘tissue engineering’ was officially coined at a National Science Foundation 
workshop in 1988 to mean ‘the application of principles and methods of engineering and life 
sciences toward the fundamental understanding of structure-function relationships in normal 
and pathological mammalian tissues and the development of biological substitutes to restore, 
maintain or improve tissue function’. However, while the field of tissue engineering may be 
relatively new, the idea of replacing tissue with another goes as far back as the 16th century. 
Gasparo Tagliacozzi (1546-99), Professor of Surgery and Anatomy at the University of 
Bologna described a nose replacement that he had constructed from a forearm flap in his 
work ‘De Custorum Chirurigia per Insitionem’ (The Surgery of Defects by Implantation) 
which was published in 1597. The field of tissue engineering is highly multidisciplinary and 
draws on experts from clinical medicine, mechanical engineering, materials science, genetics, 
and related disciplines from both engineering and the life sciences. The field relies 
extensively on the use of porous 3D scaffolds to provide the appropriate environment for the 
regeneration of tissues and organs. These scaffolds essentially act as a template for tissue 
formation and are typically seeded with cells and occasionally growth factors, or subjected to 
biophysical stimuli in the form of a bioreactor; a device or system which applies different 
types of mechanical or chemical stimuli to cells4. These cell-seeded scaffolds are either 
cultured in vitro to synthesize tissues which can then be implanted into an injured site, or are 
implanted directly into the injured site, using the body’s own systems, where regeneration of 
tissues or organs is induced in vivo. This combination of cells, signals and scaffold is often 
referred to as a tissue engineering triad (Fig. 1). In this review, the term ‘tissue engineered 
construct’ is used to identify scaffolds which have undergone extensive in vitro culture prior 
to implantation. The term scaffold refers to the 3D biomaterial before cells have been added 
(in vitro or in vivo). 
 
Scaffold requirements 
Numerous scaffolds produced from a variety of biomaterials and manufactured using a 
plethora of fabrication techniques have been used in the field in attempts to regenerate 
different tissues and organs in the body. Regardless of the tissue type, a number of key 
considerations are important when designing or determining the suitability of a scaffold for 
use in tissue engineering:   
(i) Biocompatibility  
The very first criterion of any scaffold for tissue engineering is that it must be biocompatible; 
cells must adhere, function normally, and migrate onto the surface and eventually through the 
scaffold and begin to proliferate before laying down new matrix. After implantation, the 
scaffold or tissue engineered construct must elicit a negligible immune reaction in order to 
prevent it causing such a severe inflammatory response that it might reduce healing or cause 
rejection by the body.  
(ii) Biodegradability 
The objective of tissue engineering is to allow the body’s own cells, over time, to eventually 
replace the implanted scaffold or tissue engineered construct. Scaffolds and constructs, are 
not intended as permanent implants. The scaffold must therefore be biodegradable so as to 
allow cells to produce their own extracellular matrix5. The by-products of this degradation 
should also be non-toxic and able to exit the body without interference with other organs. In 
order to allow degradation to occur in tandem with tissue formation, an inflammatory 
response combined with controlled infusion of cells such as macrophages is required. Now 
that tissue engineering strategies are entering clinical practice more routinely, the field of 
immunology is a playing a role of increasing prominence in the research area6,7.  
(iii) Mechanical properties 
Ideally, the scaffold should have mechanical properties consistent with the anatomical site 
into which it is to be implanted and, from a practical perspective, it must be strong enough to 
allow surgical handling during implantation. While this is important in all tissues, it provides 
some challenges for cardiovascular and orthopedic applications specifically. Producing 
scaffolds with adequate mechanical properties is one of the great challenges in attempting to 
engineer bone or cartilage. For these tissues, the implanted scaffold must have sufficient 
mechanical integrity to function from the time of implantation to the completion of the 
remodeling process8. A further challenge is that healing rates vary with age; for example, in 
young individuals, fractures normally heal to the point of weight-bearing in about six weeks, 
with complete mechanical integrity not returning until approximately one year after fracture, 
but in the elderly the rate of repair slows down. This too must be taken into account when 
designing scaffolds for orthopedic applications. However, as the field has evolved, it could be 
argued that too much focus has been placed on trying to develop scaffolds with mechanical 
properties similar to bone and cartilage. Many materials have been produced with good 
mechanical properties but to the detriment of retaining a high porosity and many materials, 
which have demonstrated potential in vitro have failed when implanted in vivo due to 
insufficient capacity for vascularization. It is clear that a balance between mechanical 
properties and porous architecture sufficient to allow cell infiltration and vascularization is 
key to the success of any scaffold.  
(iv) Scaffold architecture 
The architecture of scaffolds used for tissue engineering is of critical importance. Scaffolds 
should have an interconnected pore structure and high porosity to ensure cellular penetration 
and adequate diffusion of nutrients to cells within the construct and to the extra-cellular 
matrix formed by these cells. Furthermore, a porous interconnected structure is required to 
allow diffusion of waste products out of the scaffold, and the products of scaffold degradation 
should be able to exit the body without interference with other organs and surrounding 
tissues. The issue of core degradation, arising from lack of vascularization and waste removal 
from the centre of tissue engineered constructs, is of major concern in the field of tissue 
engineering9,10. Another key component is the mean pore size of the scaffold. Cells primarily 
interact with scaffolds via chemical groups (ligands) on the material surface. Scaffolds 
synthesized from natural extracellular materials (e.g. collagen) naturally possess these ligands 
in the form of Arg-Gly-Asp (RGD) binding sequences (Fig. 2), whereas scaffolds made from 
synthetic materials may require deliberate incorporation of these ligands through, for 
example, protein adsorption. The ligand density is influenced by the specific surface area, i.e. 
the available surface within a pore to which cells can adhere. This depends on the mean pore 
size in the scaffold. The pores thus need to be large enough to allow cells to migrate into the 
structure, where they eventually become bound to the ligands within the scaffold, but small 
enough to establish a sufficiently high specific surface, leading to a minimal ligand density to 
allow efficient binding of a critical number of cells to the scaffold11,12. Therefore, for any 
scaffold, a critical range of pore sizes exists13,14 which may vary depending on the cell type 
used and tissue being engineered.  
(v) Manufacturing technology 
In order for a particular scaffold or tissue engineered construct to become clinically and 
commercially viable, it should be cost effective and it should be possible to scale-up from 
making one at a time in a research laboratory to small batch production15. The development 
of scalable manufacturing processes to good manufacturing practice (GMP) standard is 
critically important in ensuring successful translation of tissue engineering strategies to the 
clinic16. Another key factor is determining how a product will be delivered and made 
available to the clinician. This will determine how either the scaffold or the tissue engineered 
construct will be stored. Clinicians typically prefer off-the shelf availability without the 
requirement for extra surgical procedures in order to harvest cells prior to a number of weeks 
of in vitro culture before implantation. However, for some tissue types, this is not possible 
and in vitro engineering prior to implantation is required.  
 
The final criterion for scaffolds in tissue engineering, and the one which all of the criteria 
listed above are dependent upon, is the choice of biomaterial from which the scaffold should 
be fabricated.  
 
Biomaterials 
In the first Consensus Conference of the European Society for Biomaterials (ESB) in 1976, a 
biomaterial was defined as ‘a nonviable material used in a medical device, intended to 
interact with biological systems’; however, the ESB’s current definition is a ‘material 
intended to interface with biological systems to evaluate, treat, augment or replace any tissue, 
organ or function of the body’. This subtle change in definition is indicative of how the field 
of biomaterials has evolved. Biomaterials have moved from merely interacting with the body 
to influencing biological processes toward the goal of tissue regeneration. 
Typically, three individuals groups of biomaterials, ceramics, synthetic polymers and natural 
polymers, are used in the fabrication of scaffolds for tissue engineering. Each of these 
individual biomaterial groups has specific advantages and, needless to say, disadvantages so 
the use of composite scaffolds comprised of different phases is becoming increasingly 
common. Although not generally used for soft tissue regeneration, there has been widespread 
use of ceramic scaffolds, such as hydroxyapatite (HA) and tri-calcium phosphate (TCP), for 
bone regeneration applications. Ceramic scaffolds are typically characterized by high 
mechanical stiffness (Young’s modulus), very low elasticity, and a hard brittle surface. From 
a bone perspective, they exhibit excellent biocompatibility due to their chemical and 
structural similarity to the mineral phase of native bone. The interactions of osteogenic cells 
with ceramics are important for bone regeneration as ceramics are known to enhance 
osteoblast differentiation and proliferation17,18. Various ceramics have been used in dental 
and orthopedic surgery to fill bone defects and to coat metallic implant surfaces to improve 
implant integration with the host bone. However, their clinical applications for tissue 
engineering has been limited because of their brittleness, difficulty of shaping for 
implantation and new bone formed in a porous HA network cannot sustain the mechanical 
loading needed for remodeling19. In addition, although HA is a primary constituent of bone 
and might seem ideal as a bone graft substitute, problems also exist in that it is difficult to 
control its degradation rate20,21.  
 
Numerous synthetic polymers have been used in the attempt to produce scaffolds including 
polystyrene, poly-l-lactic acid (PLLA), polyglycolic acid (PGA) and poly-dl-lactic-co-
glycolic acid (PLGA). While these materials have shown much success as they can be 
fabricated with a tailored architecture, and their degradation characteristics controlled by 
varying the polymer itself or the composition of the individual polymer22-24, they have 
drawbacks including the risk of rejection due to reduced bioactivity. In addition, concerns 
exist about the degradation process of PLLA and PGA as they degrade by hydrolysis, 
producing carbon dioxide and therefore lowering the local pH which can result in cell and 
tissue necrosis25. The third commonly used approach is the use of biological materials as 
scaffold biomaterials. Biological materials such as collagen, various proteoglycans, alginate-
based substrates and chitosan have all been used in the production of scaffolds for tissue 
engineering. Unlike synthetic polymer-based scaffolds, natural polymers are biologically 
active and typically promote excellent cell adhesion and growth. Furthermore, they are also 
biodegradable and so allow host cells, over time, to produce their own extracellular matrix 
and replace the degraded scaffold. However, fabricating scaffolds from biological materials 
with homogeneous and reproducible structures presents a challenge. In addition, the scaffolds 
generally have poor mechanical properties, which limits their use in, for example, load-
bearing orthopedic applications.  
 
The problems described above that exist with using scaffolds fabricated from a single phase 
biomaterial have resulted in much research being devoted to the development of composite 
scaffolds comprising a number of phases. For example, a number of groups have attempted to 
introduce ceramics into polymer-based scaffolds26-29 while others have combined synthetic 
polymers with natural polymers29,30 in order to enhance their biological capacity. While 
composite scaffolds such as these have shown some promise, each consists of at least one 
phase which is not found naturally in the body and they all have associated problems with 
biocompatibility, biodegradability or both. A more typical approach is the use of collagen-
based scaffolds, either alone or with an additional phase incorporated to enhance biological 
and/or mechanical properties (Fig. 3). This is the approach used in our laboratory particularly 
for bone regeneration but increasingly for other applications such as cartilage and 
cardiovascular repair.  
Case study: collagen scaffolds for bone tissue engineering 
Collagen is the most common protein in the body and provides strength and structural 
stability to tissues in the body including skin, blood vessels, tendon, cartilage and bone. 
Along with hydroxyapatite, collagen is one of the two major components of bone. It makes 
up 89 % of the organic matrix and 32 % of the volumetric composition of bone. As such, it 
has significant potential for culturing cells to produce bone. In our laboratory, we typically 
combine collagen (Type I) with gycosaminoglycan, a polysaccharide found in many tissues 
in the body, and, using a controlled freeze drying process, produce a highly porous collagen-
GAG (CG) scaffold. The scaffolds we have developed are variants of the very first scaffold 
developed for tissue engineering applications. These were developed by Prof. Ioannis Yannas 
in MIT and received FDA approval to regenerate skin in burns patients11,31-33. The 
development of the scaffold by Yannas, and subsequent clinical approval, was one the key 
steps in the embryogenesis of the field of tissue engineering and led to the formation of 
Integra Life Sciences who still sell the CG dermal graft and are now one of the leading 
companies in regenerative medicine worldwide.  
 
In common with all natural polymers, one major problem with using collagen as the main 
constituent of a scaffold for orthopedic tissue engineering is that it has relatively poor 
mechanical properties. However, we have demonstrated that the compressive and tensile 
mechanical properties of collagen and CG scaffolds can be improved through physical and 
chemical crosslinking methods34-36. We have also identified the optimal composition for 
osteogenesis37 and optimal pore structure to facilitate bone tissue formation12-14,38,39. Taken 
together, these studies have led to the development of a CG scaffold with an optimized 
composition, crosslinking density and pore size for bone regeneration and we have 
demonstrated the ability of these scaffolds to heal bone defects in vivo in minimally loaded 
calvarial defects7,40. However, while these CG scaffolds have shown immense promise for 
bone repair in minimally weight-bearing regions of the body; in order to facilitate repair of 
regions where the scaffolds are subjected to higher levels of loading, we have strengthened 
these collagen-based scaffolds by introducing a ceramic phase41 and have thus developed a 
series of highly porous biomimetic collagen-hydroxyapatite (CHA) scaffolds (Fig. 3) based 
on the two primary constituents of bone.  
 
These scaffolds not only possess significantly increased mechanical properties compared to a 
CG scaffold while retaining the highly porous and interconnected pore structure42-44, but also 
show improved permeability which benefits cell infiltration and subsequent vascularization 
(Fig. 4). A comparative in vivo analysis between the CHA and CG scaffolds has 
demonstrated enhanced healing in the former scaffold7. The reasons for this are two-fold: (i) 
the enhanced mechanical properties and permeability provided by the CHA scaffold allowed 
improved cellular infiltration and vascularization and (ii) the presence of calcium phosphate 
produced an osteoinductive response whereby its chemical composition enhanced the 
osteogenic potential of the host cells resulting in increased bone formation (Fig. 5)45. The 
osteoinductive potential of calcium phosphates has been noted previously46-49. The presence 
of the HA phase in these biomimetic scaffolds thus also imparts a bioinstructive facet to the 
materials. We also compared healing in cell-free scaffolds and scaffolds which had been 
cultured with mesenchymal stem cells (MSCs) for 4 weeks prior to implantation i.e. an in 
vitro tissue engineered approach7. Interestingly, we found reduced healing in the tissue 
engineered constructs which was caused, as revealed by immunological analysis, by excess 
matrix deposited by MSCs during in vitro culture, which adversely affected healing by acting 
as a barrier to macrophage-led remodeling when implanted in vivo (Fig. 6). In other words, 
the study demonstrated that in addition to tissue engineered constructs failing after 
implantation because the scaffolds are insufficiently porous, they may also fail if the in vitro 
engineered tissue which has been formed on the scaffolds has been over-engineered leading 
to core degradation following implantation. This is consistent with a number of studies which 
have demonstrated how a major barrier to clinical success in the field of tissue engineering is 
this issue of core degradation9,10,50-52.  
 
Scaffolds for tissue engineering: state of the art and future directions 
The challenge of tissue engineering is to mimic what happens in nature. Attempts are being 
made to engineer in vitro practically every tissue and organ in the body. Work is proceeding 
in creating tissue-engineered liver, nerve, kidney, intestine, pancreas and even heart muscle 
and valves. In the area of connective tissues, work has been ongoing worldwide for many 
years in the engineering of tendon, ligament, bone and cartilage. To date the highest rates of 
success have been achieved in the areas of skin11, bladder53, airway54 and bone55,56, where 
tissue-engineered constructs have been used successfully in patients. In addition, autologous 
chondrocyte implantation (ACI) and matrix-induced autologous chondrocyte implantation 
(MACI) are showing some success for cartilage repair. This latter approach involves 
culturing harvested autologous chondrocytes on a collagen-based membrane for a number of 
weeks in Genzyme’s GMP-certified laboratories prior to the construct being shipped back to 
the patient’s hospital, followed by implantation at the injured site. This product is currently 
approved for use in Europe and Australasia.  
 
While major breakthroughs have taken place and economic activity within the tissue 
engineering sector has grown exponentially, with increasing numbers of products entering the 
market place and into clinical trials, and with sales of regenerative biomaterials already 
exceeding US$240 million per annum57, significant research is required in a number of 
specific areas in the field58. As described above, lack of vascularity in scaffolds and tissue 
engineered constructs is a major challenge, and improving vascularization strategies is 
considered one of the areas requiring the most extensive research in the field of tissue 
engineering59-62. One way to improve vascularization might to be engineer microvasculature 
by cells in the scaffolds prior to implantation and a large body of work in this area is ongoing 
by a number of groups62-65 including ourselves66 (Fig. 7). This is a complex approach and 
from a clinical perspective would involve initially harvesting cells from a patient/donor, then 
engineering a nascent microvasculature followed by engineering the desired matrix/tissue 
around this microvasculature; all of which would have to be achieved prior to implantation 
into a patient. Many clinicians question the efficacy of in vitro tissue engineering due to the 
requirement for at least two procedures and the delay in treatment while the construct is being 
cultured in vitro. From a commercial perspective, this approach also poses problems due to 
the prolonged regulatory process required before such a tissue engineered construct can be 
approved for clinical use. However, in tissues such as cartilage, which do not have the ability 
to regenerate themselves when damaged, long term in vitro tissue engineering may be the 
only solution to prevent the requirement of an eventual joint arthroplasty.  
 
Other tissues, such as bone for example, have an intrinsic ability to repair, remodel and 
regenerate. The task in the field of tissue engineering is therefore to try and harness this 
innate regenerative capacity. One way to do so might be to engineer the scaffold in such a 
way that the scaffold itself provides regenerative signals to the cells which might negate the 
requirement for prolonged in vitro culture prior to implantation. Therefore, much ongoing 
research is devoted to developing more sophisticated biomimetic biomaterials with added 
levels of complexity to incorporate multi-functionality and to encourage the biomaterials to 
have, for example, bioinstructive and stimuli-responsive properties (see review67). Cells 
derive a vast wealth of information from their environment. The native extra-cellular matrix 
(ECM) surrounded, and produced, by cells is instructive, providing a dynamic and spatially 
heterogeneous constellation of microstructural, compositional and mechanical cues that can 
influence cell behavior. Harnessing the mechanosensitive capacity of cells, in particular, 
provides immense opportunities. The mechanical properties of tissues, biomaterials, cells, 
and biomolecules have profound biological consequences in terms of implant bioactivity 
versus failure, transmission of mechanical stimuli, and for a wide range of processes at the 
tissue, cell and subcellular levels. Key roles in molecular signaling pathways are played by 
cell adhesion complexes and the cellular cytoskeleton, whose contractile forces are 
transmitted through transcellular structures. Therefore, the mechanical properties of the 
substrate to which the cells are attached are critical to the regulation of cellular 
mechanotransduction and subsequent cellular behavior. This has important implications for 
development, differentiation, disease, and regeneration. It is now clear, for example, that 
substrate stiffness can regulate both the behavior of mature cells68,69 and the differentiation 
pathway of stem cells (see review70). For example, when MSCs were grown on firm gels that 
mimic the elasticity of muscle, differentiation down a myogenic (muscle-forming) lineage 
was observed, whereas when MSCs were grown on rigid gels that mimic pre-calcified bone 
the cells differentiated down an osteogenic pathway71. Similarly, with neural stem cells, 
neuron differentiation is favored on soft scaffolds that mimic normal brain tissue, whereas 
differentiation into neuron-supporting glial cells is promoted on harder matrices72. In 
addition, cardiomyocytes (heart muscle cells) have been shown to beat best on a substrate 
with heart-like elasticity, whereas on harder substrates, that mechanically mimic a post-
infarct fibrotic scar, cells overstrain themselves and stop beating73. Therefore, increasing 
research is now being directed at utilizing the mechanosensitive capacity of cells to develop 
scaffolds and biomaterials with specific mechanical properties which can be used to direct the 
behavior of the cells with which they interact36,74-77.   
 
In addition to biomechanical signals, cellular behavior is strongly influenced by biological 
and biochemical signals from the extracellular matrix. Therefore, the use of scaffolds as 
delivery systems for growth factors, adhesion peptides and cytokines is receiving 
considerable attention in the field67,70,78,79. The incorporation of, for example, angiogenic 
growth factors in scaffolds might also improve their vascular potential. Similarly, methods of 
providing nerve supply to newly formed tissues also need to be considered80. Another area of 
critical importance is controlling, and understanding, the host immune response and 
preventing infection following implantation. To this end, the incorporation of drugs (i.e. 
inflammatory inhibitors and/or antibiotics) into scaffolds has been proposed as a method to 
reduce the possibility of infection after surgery81. Finally, the use of scaffolds as delivery 
systems for therapeutic genes is undergoing considerable investigation82-87. Gene therapy 
approaches (viral and non-viral) which utilize DNA encoding for therapeutic genes 
potentially provide a more stable and effective approach to allow sustained and controlled 
release of therapeutic factors. Gene therapy can thus be a valuable tool to avoid the 
limitations of the local delivery of growth factors, including the short half-life, large dose 
requirement, high cost, need for repeated applications, and poor distribution88. The idea of a 
gene delivery vector contained within a scaffold, although not new, is a recent development 
in the field of regenerative medicine and the system has been coined as a ‘gene activated 
matrix’ (GAM) by Bonadio and co-authors89 who developed the very first system. Despite the 
prolonged regulatory process required to enter the clinical arena, such a GAM might offer 
advantages by increasing the rate of DNA delivery into the cells which are in contact with the 
gene-eluting scaffold and provide spatial and temporal control of the desired gene.  
 
These areas of new and expanding research demonstrate just how multidisciplinary the field 
of tissue engineering has become and while the challenges are vast, the opportunities for 
improving human health in a whole variety of areas are immense. Undoubtedly exciting times 
lie ahead in this field, which is only now beginning to define itself as more technologies enter 
the clinical and commercial arenas. 
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Fig. 1. Tissue engineering triad of cells, signals (provided chemically by growth factors or 
physically by a bioreactor), and the scaffold which acts as a template for tissue formation by 
allowing cells to migrate, adhere, and produce tissue. 
 
Fig. 2. Confocal micrograph showing osteoblast cells (green) attached to a highly porous 
collagen-GAG scaffold (red). The mechanism by which cells attach to biomaterials and 
scaffolds for tissue engineering is critically important for successful tissue regeneration. 
 
Fig. 3. Comparative SEM images of (a) collagen-GAG (CG) scaffold (b) hydroxyapatite 
(HA) and (c) composite collagen-HA (CHA) scaffold. The high porosity of the CG scaffold, 
which promotes improved cell infiltration and vascularization, is evident. The drawback is 
that it has poor mechanical properties. The HA scaffold has better mechanical properties but 
poorer capacity for cell infiltration and vascularization. By producing a CHA scaffold (c), it 
is possible to overcome the problems with both materials while retaining their positive 
attributes. The high porosity of the CHA scaffold and uniform distribution of HA particles 
(green dots) can clearly be seen. (a) Reproduced with permission from90, (b) Reproduced 
with permission from52. 
 
Fig. 4. Effect of hydroxyapatite addition on (a) stiffness and (b) permeability of collagen 
scaffolds. The addition of hydroxyapatite results in a significant increase in stiffness (*p < 
0.05) but also helps to improve the permeability, as the scaffold pores tend to remain open 
with no collapse following hydration. This promotes improved cell infiltration and 
subsequent vascularization after implantation. Reproduced from45. 
 
Fig. 5. Quantitative cell-mediated mineralization by osteoblasts on the CHA scaffolds 
containing differing amounts of HA (expressed as %weight with respect to collagen). ‘Blank’ 
shows original amounts of HA in the scaffolds for comparison. The presence of HA produced 
an osteoinductive response whereby its chemical composition enhanced the osteogenic 
potential of the host cells resulting in increased bone formation. Reproduced from45. 
 
Fig. 6. Example of core degradation in a rat calvarial defect treated with a tissue engineered 
collagen-calcium phosphate scaffold 4 weeks post implantation. Fig. 6(a) shows the full 
defect area. It can be seen that there is significant inflammation and a capsule (red arrows) 
has formed around the periphery of the implanted tissue engineered construct resulting in 
core degradation. Fig. 6(a) shows a higher magnification image of the defect area and it can 
be seen that the core region is completely acellular (black arrows). White arrows represent 
original host bone. Reproduced with permission from7. 
 
Fig. 7. In vitro microvessel formation by endothelial cells on the CG scaffold. In this image, 
cell-seeded constructs were labeled with AlexaFluor 488 Phalloidin (which stains the cell 
cytoskeleton green) and DAPI (which stains the cell nucleus purple). Vessel formation was 









Fig. 2: Zeiss LSM-510 confocal microscope  
Fig. 3: JEOL JSM-5410 LV scanning electron microscope 
Fig. 4: Zwick/Roell Z050 mechanical testing machine and permeability measurements were 
carried out using an in-house developed testing rig38 
Fig. 5: Titerek Multiskan MCC/340 spectrometer 
Fig. 6: Nikon Eclipse 90i epifluorescence microscope  
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